Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Follicular Lymphoma in Real World Study
About this study
This study is planned to prospectively observe and verify the efficacy and safety of induction therapy with obinutuzumab in combination with lenalidomide followed by maintenance therapy with obinutuzumab and lenalidomide in patients with R/R FL in a real-world setting in a Chinese population.
- Condition
- Follicular Lymphoma
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Who can join
- Age
- 18 years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 8
- Minimum age: 18 years
- Study condition: Follicular Lymphoma
- Patients must meet the following criteria for study entry::
- Signed Informed Consent Form
- Age ≥ 18 years at enrollment
- At least one prior line of systemic (Stage III-IV) follicular lymphoma therapy
- Relapsed or refractory to front-line anti-lymphoma therapy; refractory is defined as: tumor shrinkage of less than 50% or disease progression after 4 cycles of standard regimen chemotherapy; response to standard regimen chemotherapy, relapse within 24 months; 2 or more relapses, meeting one of the above criteria as refractory lymphoma.
- Conditional treatment with obinutuzumab in combination with lenalidomide
Exclusion 2
- Patients currently participating or planning to participate in any interventional clinical trial
- Any other reason that, in the opinion of the investigator, makes the patient unsuitable for this study
Where
1 site, 1 recruiting
Institute of Hematology and Blood Diseases Hospital ,Chinese Academy of Medical Sciences
Tianjin, China
Contact
-
shuhua Yi, Dr
86-22-23909106 yishuhua@ihcams.ac.cn
-
Lugui Qiu, Dr
86-22-23909172 qiulg@ihcams.ac.cn
Potential match only. Final eligibility is determined by the study team.